CN117377663A - 可用于治疗癌症的柔毛地胆亭衍生物 - Google Patents

可用于治疗癌症的柔毛地胆亭衍生物 Download PDF

Info

Publication number
CN117377663A
CN117377663A CN202280031592.6A CN202280031592A CN117377663A CN 117377663 A CN117377663 A CN 117377663A CN 202280031592 A CN202280031592 A CN 202280031592A CN 117377663 A CN117377663 A CN 117377663A
Authority
CN
China
Prior art keywords
cancer
groups
compound
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280031592.6A
Other languages
English (en)
Chinese (zh)
Inventor
李开洋
千叶俊介
黎素君
高正宜
翁敦和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanyang Biotechnology Co ltd
Nanyang Technological University
Original Assignee
Nanyang Herbal Medicine Co ltd
Nanyang Technological University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanyang Herbal Medicine Co ltd, Nanyang Technological University filed Critical Nanyang Herbal Medicine Co ltd
Publication of CN117377663A publication Critical patent/CN117377663A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280031592.6A 2021-04-29 2022-04-27 可用于治疗癌症的柔毛地胆亭衍生物 Pending CN117377663A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202104429U 2021-04-29
SG10202104429U 2021-04-29
PCT/SG2022/050251 WO2022231520A1 (en) 2021-04-29 2022-04-27 Molephantin derivatives useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
CN117377663A true CN117377663A (zh) 2024-01-09

Family

ID=83848883

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280031592.6A Pending CN117377663A (zh) 2021-04-29 2022-04-27 可用于治疗癌症的柔毛地胆亭衍生物

Country Status (7)

Country Link
US (1) US20250304544A1 (https=)
EP (1) EP4330241A4 (https=)
JP (1) JP2024517443A (https=)
CN (1) CN117377663A (https=)
AU (1) AU2022265461A1 (https=)
IL (1) IL308058A (https=)
WO (1) WO2022231520A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919833A (zh) * 2023-01-31 2023-04-07 暨南大学附属第一医院（广州华侨医院） 一种CutC蛋白抑制剂及其应用
AU2024337402A1 (en) * 2023-09-06 2026-03-26 Nanyang Biologics Pte. Ltd. Collective synthesis of phantomolin family through total synthesis of the sesquiterpene lactone molephantin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058888A1 (en) * 2000-02-10 2001-08-16 Motoyoshi Satake A sesquiterpenoic compound and pharmaceutical formulations comprising the same
JP2005002050A (ja) * 2003-06-12 2005-01-06 Shiseido Co Ltd 美白剤及びこれを配合した皮膚外用剤
CN102000072A (zh) * 2009-09-01 2011-04-06 奇复康药物研发(苏州)有限公司 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途
CN103732586A (zh) * 2011-04-07 2014-04-16 南洋理工大学 作为抗癌剂的乙酰基丹参酮iia(ata)
CN111153910A (zh) * 2020-01-09 2020-05-15 沈阳药科大学 地胆草种内酯衍生物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040335A1 (en) * 2017-08-19 2019-02-28 University Of Rochester MICHELOLID DERIVATIVES, PREPARATION METHODS AND THEIR USE AS ANTICANCER AND ANTI-INFLAMMATORY AGENTS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058888A1 (en) * 2000-02-10 2001-08-16 Motoyoshi Satake A sesquiterpenoic compound and pharmaceutical formulations comprising the same
JP2005002050A (ja) * 2003-06-12 2005-01-06 Shiseido Co Ltd 美白剤及びこれを配合した皮膚外用剤
CN102000072A (zh) * 2009-09-01 2011-04-06 奇复康药物研发(苏州)有限公司 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途
CN103732586A (zh) * 2011-04-07 2014-04-16 南洋理工大学 作为抗癌剂的乙酰基丹参酮iia(ata)
CN111153910A (zh) * 2020-01-09 2020-05-15 沈阳药科大学 地胆草种内酯衍生物及其制备方法和用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACS: "RN:1214983-64-8", STN REGISTRY 数据库, 26 March 2010 (2010-03-26), pages 1 - 2 *
GENARO C. POLLORA等: "Elephantopus-type sesquiterpene lactones from a second Vernonanthura species, Vernonanthura lipeoensis", BIOCHEMICAL SYSTEMATICS AND ECOLOGY, vol. 32, 31 December 2004 (2004-12-31), pages 619 *
HIROYUKI FUCHINO等: "New sesquiterpene lactones from Elephantopus mollis and their leishmanicidal activities", PLANTA MED, vol. 67, 31 December 2001 (2001-12-31), pages 647 *
KUO-HSIUNG LEE等: "Antitumor agents. XXXVIII: Isolation and structural elucidation of novel germacranolides and triterpenes from Elephantopus mollis", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 68, no. 9, 30 September 1980 (1980-09-30), pages 1050 *

Also Published As

Publication number Publication date
AU2022265461A1 (en) 2023-11-16
IL308058A (en) 2023-12-01
JP2024517443A (ja) 2024-04-22
US20250304544A1 (en) 2025-10-02
EP4330241A4 (en) 2025-03-19
EP4330241A1 (en) 2024-03-06
WO2022231520A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
US20250074873A1 (en) Compounds
US20250163044A1 (en) Compounds
JP7787811B2 (ja) ＭｒｇｐｒＸ２アンタゴニストおよびその使用
JP7297827B2 (ja) Ｃｆｔｒ制御因子及びこの使用方法
WO2022199627A1 (en) Polycyclic compounds and uses thereof
CN117377663A (zh) 可用于治疗癌症的柔毛地胆亭衍生物
EP3394083A1 (en) Cftr regulators and methods of use thereof
JP2020537667A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
JP2025081626A (ja) ペンタミジンの類似体及びその使用
AU2006216031A1 (en) Anti-tumor agent
EP3883918B1 (en) Rip1 inhibitors
CN105189446B (zh) 间苯三酚类衍生物及其在治疗神经退行性疾病中的用途
KR102743295B1 (ko) Cftr 조절제 및 이의 이용 방법
WO2017142269A1 (ko) 신규한 인돌 유도체 및 이를 포함하는 항암 조성물
CN121969392A (zh) 一种药物组合及其用途
WO2024235218A1 (zh) Hdac1/2选择性抑制剂及其用途
CN114149395B (zh) 一种苯并环戊烯酮衍生物、其制备方法及医药用途
JP2024510249A (ja) 神経疾患を治療するための組成物およびその方法
CN116761598A (zh) Fabp4调节化合物的抗病毒用途
CN106554349A (zh) 野八角新异戊烯基取代c6‑c3类化合物及其制备方法、应用和其药物组合物
CN116987091B (zh) 用于治疗癫痫发作疾病的药物及其制备方法
US20240383892A1 (en) PARTICLES OF IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS
WO2014152869A2 (en) Benzyl urea derivatives for activating tgf-beta signaling
JP2019156798A (ja) 多発性骨髄腫の治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250507

Address after: Singapore City

Applicant after: NANYANG TECHNOLOGICAL University

Country or region after: Singapore

Applicant after: Nanyang Biotechnology Co.,Ltd.

Address before: Singapore City

Applicant before: NANYANG TECHNOLOGICAL University

Country or region before: Singapore

Applicant before: Nanyang Herbal Medicine Co.,Ltd.